Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment
OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads...
Gespeichert in:
Veröffentlicht in: | Psychiatric services (Washington, D.C.) D.C.), 2001-04, Vol.52 (4), p.501-507 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 507 |
---|---|
container_issue | 4 |
container_start_page | 501 |
container_title | Psychiatric services (Washington, D.C.) |
container_volume | 52 |
creator | Noordsy, Douglas L. O'Keefe, Christopher Mueser, Kim T. Xie, Haiyi |
description | OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients. |
doi_str_mv | 10.1176/appi.ps.52.4.501 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77012569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77012569</sourcerecordid><originalsourceid>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</originalsourceid><addsrcrecordid>eNp1kEtLAzEURoMotlb3rmRAcDfjTSYPZyn1CZUKrbgMmTRDp3QmY5LBx683tUVXru5dnO9-l4PQKYYMY8EvVdfVWeczRjKaMcB7aIgZE2khAPbjDoKlROQwQEferwAAC8wP0QBjIigtxBDdzOqP9Mm2YZlM-6BtY3xSWZc8q1CbNvjkdWmT2Xsd9NIskmCT6Vq1X6qrW5PMnVGhidQxOqjU2puT3Ryhl7vb-fghnUzvH8fXk1RRxkMqNIAmmqnCCMEVxcAXvAANJRClckKAkWrBK0bLEoTAhDBtODUxcMULQvIRutje7Zx9640Psqm9Nuv4krG9l0IAJowXEYQtqJ313plKdq5ulPuUGOTGnNyYk52XjEgqo7kYOdvd7svGLP4CO1URON8Bymu1rpxqde1_uYIymm-a0y31U7CyvWujkf9rvwEPyIWN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77012569</pqid></control><display><type>article</type><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</creator><creatorcontrib>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</creatorcontrib><description>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</description><identifier>ISSN: 1075-2730</identifier><identifier>EISSN: 1557-9700</identifier><identifier>DOI: 10.1176/appi.ps.52.4.501</identifier><identifier>PMID: 11274497</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - therapeutic use ; Benzodiazepines ; Biological and medical sciences ; Brief Psychiatric Rating Scale ; Chlorpromazine - administration & dosage ; Chlorpromazine - therapeutic use ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Medical sciences ; Mental Disorders - diagnosis ; Mental Disorders - drug therapy ; Mental Disorders - psychology ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Pirenzepine - administration & dosage ; Pirenzepine - analogs & derivatives ; Pirenzepine - therapeutic use ; Prospective Studies ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Severity of Illness Index ; Time Factors ; Treatment Outcome</subject><ispartof>Psychiatric services (Washington, D.C.), 2001-04, Vol.52 (4), p.501-507</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</citedby><cites>FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ps.52.4.501$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ps.52.4.501$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2853,2857,21624,21625,21626,21627,27922,27923,77561,77562,77564,77569</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=945439$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11274497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noordsy, Douglas L.</creatorcontrib><creatorcontrib>O'Keefe, Christopher</creatorcontrib><creatorcontrib>Mueser, Kim T.</creatorcontrib><creatorcontrib>Xie, Haiyi</creatorcontrib><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><title>Psychiatric services (Washington, D.C.)</title><addtitle>Psychiatr Serv</addtitle><description>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</description><subject>Adult</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines</subject><subject>Biological and medical sciences</subject><subject>Brief Psychiatric Rating Scale</subject><subject>Chlorpromazine - administration & dosage</subject><subject>Chlorpromazine - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Disorders - diagnosis</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - psychology</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pirenzepine - administration & dosage</subject><subject>Pirenzepine - analogs & derivatives</subject><subject>Pirenzepine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1075-2730</issn><issn>1557-9700</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEURoMotlb3rmRAcDfjTSYPZyn1CZUKrbgMmTRDp3QmY5LBx683tUVXru5dnO9-l4PQKYYMY8EvVdfVWeczRjKaMcB7aIgZE2khAPbjDoKlROQwQEferwAAC8wP0QBjIigtxBDdzOqP9Mm2YZlM-6BtY3xSWZc8q1CbNvjkdWmT2Xsd9NIskmCT6Vq1X6qrW5PMnVGhidQxOqjU2puT3Ryhl7vb-fghnUzvH8fXk1RRxkMqNIAmmqnCCMEVxcAXvAANJRClckKAkWrBK0bLEoTAhDBtODUxcMULQvIRutje7Zx9640Psqm9Nuv4krG9l0IAJowXEYQtqJ313plKdq5ulPuUGOTGnNyYk52XjEgqo7kYOdvd7svGLP4CO1URON8Bymu1rpxqde1_uYIymm-a0y31U7CyvWujkf9rvwEPyIWN</recordid><startdate>20010401</startdate><enddate>20010401</enddate><creator>Noordsy, Douglas L.</creator><creator>O'Keefe, Christopher</creator><creator>Mueser, Kim T.</creator><creator>Xie, Haiyi</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010401</creationdate><title>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</title><author>Noordsy, Douglas L. ; O'Keefe, Christopher ; Mueser, Kim T. ; Xie, Haiyi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a456t-7c00c2c5a9e776a4106d690c0b02aa322052fd6f54bb0771225ce64e5a9869223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines</topic><topic>Biological and medical sciences</topic><topic>Brief Psychiatric Rating Scale</topic><topic>Chlorpromazine - administration & dosage</topic><topic>Chlorpromazine - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Disorders - diagnosis</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - psychology</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pirenzepine - administration & dosage</topic><topic>Pirenzepine - analogs & derivatives</topic><topic>Pirenzepine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noordsy, Douglas L.</creatorcontrib><creatorcontrib>O'Keefe, Christopher</creatorcontrib><creatorcontrib>Mueser, Kim T.</creatorcontrib><creatorcontrib>Xie, Haiyi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric services (Washington, D.C.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noordsy, Douglas L.</au><au>O'Keefe, Christopher</au><au>Mueser, Kim T.</au><au>Xie, Haiyi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment</atitle><jtitle>Psychiatric services (Washington, D.C.)</jtitle><addtitle>Psychiatr Serv</addtitle><date>2001-04-01</date><risdate>2001</risdate><volume>52</volume><issue>4</issue><spage>501</spage><epage>507</epage><pages>501-507</pages><issn>1075-2730</issn><eissn>1557-9700</eissn><abstract>OBJECTIVE: This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS: Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS: At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS: Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>11274497</pmid><doi>10.1176/appi.ps.52.4.501</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1075-2730 |
ispartof | Psychiatric services (Washington, D.C.), 2001-04, Vol.52 (4), p.501-507 |
issn | 1075-2730 1557-9700 |
language | eng |
recordid | cdi_proquest_miscellaneous_77012569 |
source | MEDLINE; American Psychiatric Publishing Journals (1997-Present); Psychiatry Legacy Collection Online Journals 1844-1996; EZB-FREE-00999 freely available EZB journals |
subjects | Adult Antipsychotic Agents - administration & dosage Antipsychotic Agents - therapeutic use Benzodiazepines Biological and medical sciences Brief Psychiatric Rating Scale Chlorpromazine - administration & dosage Chlorpromazine - therapeutic use Dose-Response Relationship, Drug Female Humans Male Medical sciences Mental Disorders - diagnosis Mental Disorders - drug therapy Mental Disorders - psychology Middle Aged Neuropharmacology Pharmacology. Drug treatments Pirenzepine - administration & dosage Pirenzepine - analogs & derivatives Pirenzepine - therapeutic use Prospective Studies Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Severity of Illness Index Time Factors Treatment Outcome |
title | Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Six-Month%20Outcomes%20for%20Patients%20Who%20Switched%20to%20Olanzapine%20Treatment&rft.jtitle=Psychiatric%20services%20(Washington,%20D.C.)&rft.au=Noordsy,%20Douglas%20L.&rft.date=2001-04-01&rft.volume=52&rft.issue=4&rft.spage=501&rft.epage=507&rft.pages=501-507&rft.issn=1075-2730&rft.eissn=1557-9700&rft_id=info:doi/10.1176/appi.ps.52.4.501&rft_dat=%3Cproquest_cross%3E77012569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77012569&rft_id=info:pmid/11274497&rfr_iscdi=true |